Why INVO Bioscience Shares Are Trading Higher By Around 73%; Here Are 20 Stocks Moving Premarket

Benzinga ·  Apr 17 06:18

Shares of $INVO Bioscience (INVO.US)$ rose sharply in today's pre-market trading after reporting fourth-quarter results.

The company said quarterly revenue surged 397% year-over-year to $1,381,754, from $278,142 in the year-ago period, according to data from Benzinga Pro.

INVO Bioscience shares jumped 73.1% to $1.35 in pre-market trading.

Here are some other stocks moving in pre-market trading.



  • Connexa Sports Technologies Inc. fell 32.3% to $1.42 in pre-market trading.

  • $Dynatronics (DYNT.US)$ fell 19.2% to $0.4442 in pre-market trading after gaining around 48% on Tuesday.

  • $Destiny Tech100 (DXYZ.US)$ fell 17.3% to $35.97 in pre-market trading after gaining around 18% on Tuesday.

  • $WiSA Technologies (WISA.US)$ fell 15.2% to $5.17 in pre-market trading. WiSA shares jumped over 248% on Tuesday after the company announced a 5-year WiSA E licensing agreement with an HDTV/PTV brand.

  • $Dragonfly Energy (DFLI.US)$ declined 14.8% to $0.5232 in pre-market trading. Dragonfly Energy shares jumped over 36% on Tuesday after the company reported better-than-expected fourth-quarter EPS results.

  • $China SXT Pharmaceuticals (SXTC.US)$ fell 14.7% to $1.38 pre-market trading. China SXT Pharmaceuticals shares jumped 38% on Tuesday following a post on X from trader Zack Morris mentioning the stock.

  • $Trilogy Metals (TMQ.US)$ shares fell 14.4% to $0.43 in pre-market trading.

  • $Trio Petroleum (TPET.US)$ fell 12.8% to $0.4250 pre-market trading after dipping over 22% on Tuesday.

  • $JB Hunt Transport Services (JBHT.US)$ shares fell 6% to $172.00 in pre-market trading after the company missed first-quarter revenue and EPS estimates.

  • $ASML Holding (ASML.US)$ shares declined 4.9% to $929.00 in pre-market trading after the company reported worse-than-expected first-quarter results and issued second-quarter guidance.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment